Documents
Application Sponsors
NDA 204369 | BAYER HEALTHCARE PHARMS | |
Marketing Status
Application Products
001 | TABLET; ORAL | 40MG | 2 | STIVARGA | REGORAFENIB |
FDA Submissions
TYPE 9; Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval | ORIG | 1 | AP | 2013-02-25 | PRIORITY |
Submissions Property Types
TE Codes
CDER Filings
BAYER HEALTHCARE PHARMS
cder:Array
(
[0] => Array
(
[ApplNo] => 204369
[companyName] => BAYER HEALTHCARE PHARMS
[docInserts] => ["",""]
[products] => [{"drugName":"STIVARGA","activeIngredients":"REGORAFENIB","strength":"40MG","dosageForm":"TABLET; ORAL","marketingStatus":"Prescription","te":"","rld":"TBD","rs":"No"}]
[labels] => [{"actionDate":"02\/25\/2013","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/204369lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"02\/25\/2013","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/204369lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2013\\\/204369Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2013\\\/204369Orig1s000TOC.cfm\"},{\"name\":\"Summary Review (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2013\\\/204369Orig1s000SumR.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2013-02-25
)
)